These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21155943)

  • 61. (99m)Tc-DTPA scintigraphy assesses the absence of glomerular filtration rate impairment of Aliskiren in high-risk hypertensive subjects. A 12-month follow-up study.
    Mazza A; Montemurro D; Maffione AM; Vescovo G; Rampin L; Zuin M; Schiavon L; Camerotto A; Marzola MC; Fiorini F; Rubello D
    Minerva Cardioangiol; 2014 Aug; 62(4):311-20. PubMed ID: 25012100
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of aliskiren- and ramipril-based treatment on central aortic blood pressure in elderly with systolic hypertension: a substudy of AGELESS.
    Baschiera F; Chang W; Brunel P;
    Vasc Health Risk Manag; 2014; 10():389-97. PubMed ID: 25061313
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of aliskiren on blood pressure and myocardial function assessed by global longitudinal strain in patients with arterial hypertension and diastolic dysfunction.
    Manov E; Shabani R; Naydenov SN; Runev NM; Donova TI
    Folia Med (Plovdiv); 2012; 54(3):30-4. PubMed ID: 23270204
    [TBL] [Abstract][Full Text] [Related]  

  • 64. 1-Year outcomes of hypertension management in 13,000 outpatients under practice conditions: prospective 3A registry.
    Zeymer U; Dechend R; Riemer T; Kaiser E; Senges J; Pittrow D; Schmieder RE;
    Int J Cardiol; 2014 Oct; 176(3):589-94. PubMed ID: 25305705
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effects of a multifaceted educational program on blood pressure and cardiovascular risk in hypertensive patients: the Austrian herz.leben project.
    Perl S; Riegelnik V; Mrak P; Ederer H; Rakovac I; Beck P; Kraler E; Stoff I; Winklehner S; Klima G; Pieske BM; Pieber TR; Zweiker R
    J Hypertens; 2011 Oct; 29(10):2024-30. PubMed ID: 21857535
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Physician attitudes to blood pressure control: findings from the Supporting Hypertension Awareness and Research Europe-wide survey.
    Redon J; Erdine S; Böhm M; Ferri C; Kolloch R; Kreutz R; Laurent S; Persu A; Schmieder RE;
    J Hypertens; 2011 Aug; 29(8):1633-40. PubMed ID: 21720274
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Finding a place for aliskiren in the wide spectrum of blood pressure lowering agents.
    Angeli F; Reboldi G; Verdecchia P
    Hypertens Res; 2012 Jan; 35(1):17-9. PubMed ID: 21937995
    [No Abstract]   [Full Text] [Related]  

  • 68. Blood pressure control and clustering of cardiovascular risk factors in Mediterranean post-menopausal hypertensive women.
    Pannarale G; Acconcia MC; Licitra R; Centaro E; Pannitteri G
    Eur Rev Med Pharmacol Sci; 2013 Apr; 17(8):1017-24. PubMed ID: 23661514
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study.
    Gradman AH; Parisé H; Lefebvre P; Falvey H; Lafeuille MH; Duh MS
    Hypertension; 2013 Feb; 61(2):309-18. PubMed ID: 23184383
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Salvage therapy with aliskiren in malignant familial hypertension in a breast-fed baby].
    Belda-Rustarazo S; Vallejo-Rodríguez I; Molina-Carballo A; Cabeza Barrera J
    Farm Hosp; 2011; 35(6):343-4. PubMed ID: 21565539
    [No Abstract]   [Full Text] [Related]  

  • 71. Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients.
    Hamarneh D; Alkhatib N; Denhaerynck K; Vancayzeele S; Brié H; MacDonald K; Abraham I
    Curr Med Res Opin; 2021 Mar; 37(3):367-375. PubMed ID: 33467935
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Blood pressure control measures and cardiovascular outcomes: a prospective hypertensive cohort.
    Sideris K; Andrikou I; Thomopoulos C; Tatakis F; Kariori M; Manta E; Kalos T; Soulaidopoulos S; Drogkaris S; Konstantinidis D; Tsioufis K
    Blood Press; 2022 Dec; 31(1):228-235. PubMed ID: 36123788
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Blood pressure variability in chronic kidney disease patients.
    Mallamaci F; Tripepi G
    Blood Purif; 2013; 36(1):58-62. PubMed ID: 23735729
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Visit-to-visit variability of blood pressure: current knowledge and future research directions.
    Muntner P; Levitan EB
    Blood Press Monit; 2013 Aug; 18(4):232-8. PubMed ID: 23676615
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Aliskiren improves nitric oxide bioavailability and limits atherosclerosis.
    Verma S; Gupta MK
    Hypertension; 2008 Sep; 52(3):467-9. PubMed ID: 18645047
    [No Abstract]   [Full Text] [Related]  

  • 76. Blood pressure control in treated hypertensive Middle Eastern patients: a post hoc analysis based on JNC8 definitions.
    Alhaddad IA; Hamoui O; Hammoudeh A; Mallat S
    Vasc Health Risk Manag; 2019; 15():35-46. PubMed ID: 30881006
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Setting blood pressure targets in patients with uncontrolled hypertension: physicians' subjective criteria].
    Ducher M; Leutenegger E; Fauvel JP
    Presse Med; 2007 Feb; 36(2 Pt 1):192-6. PubMed ID: 17259026
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Aliskiren improves blood pressure control and prevents cardiac damage in high-risk hypertensive subjects.
    Mazza A; Montemurro D; Zuin M; Schiavon L; Zorzan S; Chondrogiannis S; Ferretti A; Ramazzina E; Rubello D
    Minerva Cardioangiol; 2013 Feb; ():. PubMed ID: 23370164
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mobile APP-assisted family physician program for improving blood pressure outcome in hypertensive patients.
    Xing F; Guo Y; Xia N; Zhang S; Yin J; Qin L; Zhu C; Gao Q; Jia J; Zhao Y; Qi Y; Li W
    BMC Prim Care; 2023 Jan; 24(1):8. PubMed ID: 36627556
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Development of a parametric simulation model for forecasting goal-oriented treatment outcomes.
    Yuan Y; Chen RS; L'Italien G; Karaniewsky R
    Value Health; 2004; 7(4):482-9. PubMed ID: 15449640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.